
CONTENTS

ENVIRONMENTAL HEALTH CRITERIA ON PRINCIPLES FOR EVALUATING HEALTH RISKS IN CHILDREN ASSOCIATED WITH EXPOSURE TO CHEMICALS

| | |
|--|------|
| PREAMBLE | xi |
| PREFACE | xvii |
| ACRONYMS AND ABBREVIATIONS | xix |
| 1. SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS | 1 |
| 1.1 Summary | 1 |
| 1.2 Conclusions and recommendations | 4 |
| 2. INTRODUCTION AND BACKGROUND | 7 |
| 2.1 Introduction | 7 |
| 2.2 Purpose and scope of document | 9 |
| 2.3 Global burden of disease in children | 12 |
| 2.4 Major environmental threats to children | 14 |
| 2.4.1 Economic and nutritional factors | 15 |
| 2.4.2 Social, cultural, demographic, and lifestyle factors | 16 |
| 2.4.3 Chemical hazards | 17 |
| 2.5 Intrinsic factors | 19 |
| 2.6 The significance of a developmental stage approach | 20 |
| 2.7 Summary and conclusions | 21 |
| 3. UNIQUE BIOLOGICAL CHARACTERISTICS OF CHILDREN | 22 |
| 3.1 General physical growth of children | 22 |
| 3.1.1 Body weight and height | 22 |
| 3.1.2 Organ weights/volumes | 23 |
| 3.1.3 Skin | 25 |
| 3.2 Anatomical and functional characteristics | 25 |
| 3.3 Physiological characteristics | 26 |

| | | |
|---------|--|----|
| 3.3.1 | Breathing rate | 26 |
| 3.3.2 | Cardiac output | 26 |
| 3.3.3 | Blood flow to organs | 27 |
| 3.3.4 | Body composition | 28 |
| 3.3.5 | Tissue composition | 29 |
| 3.3.6 | Bone growth and composition | 29 |
| 3.4 | Metabolic characteristics | 29 |
| 3.5 | Toxicokinetics | 31 |
| 3.5.1 | Absorption, distribution, metabolism, and elimination | 31 |
| 3.5.2 | Physiological changes in mothers and their influence on toxicokinetics | 33 |
| 3.5.2.1 | Pregnancy | 33 |
| 3.5.2.2 | Lactation and breast milk | 35 |
| 3.5.3 | Dose to target | 36 |
| 3.6 | Normal development | 39 |
| 3.6.1 | Basic principles of normal development | 39 |
| 3.6.2 | Nervous system | 40 |
| 3.6.3 | Reproductive system | 42 |
| 3.6.4 | Endocrine system | 44 |
| 3.6.4.1 | Hypothalamic–pituitary axis | 44 |
| 3.6.4.2 | Thyroid gland | 46 |
| 3.6.4.3 | Adrenal glands | 47 |
| 3.6.4.4 | Gonads | 48 |
| 3.6.4.5 | Somatotropin (growth hormone), calcium homeostasis, and bone development | 48 |
| 3.6.4.6 | Pancreas | 48 |
| 3.6.5 | Cardiovascular system | 49 |
| 3.6.6 | Immune system | 49 |
| 3.6.7 | Respiratory system | 50 |
| 3.6.8 | Kidney | 52 |
| 3.7 | Summary and conclusions | 53 |
| 4. | DEVELOPMENTAL STAGE–SPECIFIC SUSCEPTIBILITIES AND OUTCOMES IN CHILDREN | 55 |
| 4.1 | Introduction | 55 |
| 4.2 | Mortality, growth restriction, and birth defects | 60 |
| 4.2.1 | Mortality | 60 |
| 4.2.2 | Growth restriction | 63 |
| 4.2.3 | Birth defects (structural malformations) | 64 |

| | | |
|---------|---|-----|
| 4.2.3.1 | Etiology | 66 |
| 4.2.3.2 | Functional developmental toxicity | 67 |
| 4.3 | Specific organ systems | 68 |
| 4.3.1 | Nervous system | 68 |
| 4.3.1.1 | Periods of susceptibility and consequences of exposures | 69 |
| 4.3.1.2 | Specific examples | 72 |
| 4.3.2 | Reproductive system | 78 |
| 4.3.2.1 | Periods of susceptibility | 79 |
| 4.3.2.2 | Consequences of exposures | 80 |
| 4.3.3 | Endocrine system | 85 |
| 4.3.3.1 | Periods of susceptibility | 85 |
| 4.3.3.2 | Consequences of exposures | 92 |
| 4.3.4 | Cardiovascular system | 95 |
| 4.3.4.1 | Periods of susceptibility | 96 |
| 4.3.4.2 | Consequences of exposures | 96 |
| 4.3.5 | Immune system | 97 |
| 4.3.5.1 | Periods of susceptibility | 98 |
| 4.3.5.2 | Consequences of exposures | 101 |
| 4.3.6 | Respiratory system | 105 |
| 4.3.6.1 | Periods of susceptibility | 105 |
| 4.3.6.2 | Consequences of exposures | 106 |
| 4.3.7 | Kidney | 113 |
| 4.3.7.1 | Periods of susceptibility | 113 |
| 4.3.7.2 | Consequences of exposures | 114 |
| 4.4 | Cancer | 115 |
| 4.4.1 | Childhood cancers that may have environmental causes | 116 |
| 4.4.1.1 | Lymphoid tissues | 116 |
| 4.4.1.2 | Liver | 118 |
| 4.4.1.3 | Thyroid | 118 |
| 4.4.1.4 | Brain and nervous system | 119 |
| 4.4.1.5 | Other organ sites | 119 |
| 4.4.2 | Adult cancers related to childhood exposures | 120 |
| 4.4.2.1 | Brain and nervous system | 120 |
| 4.4.2.2 | Thyroid | 121 |
| 4.4.2.3 | Female breast | 122 |
| 4.4.2.4 | Female reproductive tract | 122 |
| 4.4.2.5 | Integument | 122 |
| 4.4.2.6 | Other organ sites | 123 |

| | | |
|---------|--|-----|
| 4.4.3 | Chemical exposures of special concern | 123 |
| 4.5 | Summary and conclusions | 126 |
| 5. | EXPOSURE ASSESSMENT OF CHILDREN | 129 |
| 5.1 | Introduction | 129 |
| 5.2 | General principles of exposure assessments | 129 |
| 5.3 | Methods for conducting exposure assessments | 133 |
| 5.3.1 | Direct methods | 133 |
| 5.3.2 | Biomarkers of exposure | 136 |
| 5.3.3 | Modelling | 137 |
| 5.4 | Unique characteristics of children that affect exposure | 139 |
| 5.5 | Exposure as it relates to children around the world | 144 |
| 5.5.1 | Sources/geographical location | 144 |
| 5.5.2 | Pathways of exposure | 145 |
| 5.5.2.1 | Ambient air exposure pathway | 145 |
| 5.5.2.2 | Indoor exposure pathways | 150 |
| 5.5.2.3 | Water exposure pathway | 152 |
| 5.5.2.4 | Soil exposure pathway | 153 |
| 5.5.2.5 | Food-chain exposure pathway | 154 |
| 5.5.2.6 | Human to human exposure pathways | 155 |
| 5.5.3 | Settings/microenvironments | 156 |
| 5.5.3.1 | Residential | 157 |
| 5.5.3.2 | School | 157 |
| 5.5.3.3 | Child-care centres | 157 |
| 5.5.3.4 | Recreational | 158 |
| 5.5.3.5 | Special settings | 159 |
| 5.5.4 | Environmental equity factors (vulnerable communities) | 161 |
| 5.6 | Special considerations for children's exposure: case-studies | 162 |
| 5.6.1 | Influence of activities | 162 |
| 5.6.1.1 | Arsenic | 162 |
| 5.6.1.2 | Insecticides | 162 |
| 5.6.1.3 | Environmental tobacco smoke (ETS) | 162 |
| 5.6.1.4 | Lead | 163 |
| 5.6.2 | Hazardous waste sites | 163 |
| 5.6.3 | Aggregate exposure | 164 |
| 5.6.3.1 | Chlorpyrifos | 164 |

| | |
|---|------------|
| 5.6.3.2 Smelter areas | 165 |
| 5.6.3.3 Malarious areas | 165 |
| 5.6.4 Cumulative exposure | 165 |
| 5.7 Summary and conclusions | 166 |
| 6. METHODOLOGIES TO ASSESS HEALTH OUTCOMES IN CHILDREN | 168 |
| 6.1 Introduction | 168 |
| 6.1.1 Methodological approaches for children's health studies | 168 |
| 6.1.1.1 Epidemiological methods | 171 |
| 6.1.1.2 Comparison of study designs | 171 |
| 6.1.1.3 Descriptive designs | 176 |
| 6.1.1.4 Analytic designs | 178 |
| 6.1.1.5 Unique methodological considerations | 180 |
| 6.1.2 Methodological approaches for animal studies | 181 |
| 6.1.2.1 Developmental stage susceptibility, dosing periods, and assessment of effects | 184 |
| 6.1.2.2 Dosing of fetuses and pups | 190 |
| 6.2 Growth and development | 190 |
| 6.2.1 Human studies | 190 |
| 6.2.1.1 Puberty | 194 |
| 6.2.1.2 Birth defects | 195 |
| 6.2.2 Animal studies | 195 |
| 6.2.2.1 Body weight and postnatal growth | 195 |
| 6.2.2.2 Pre-, peri-, and postnatal death | 196 |
| 6.2.2.3 Physical and functional developmental landmarks | 196 |
| 6.2.2.4 Birth defects and malformations | 198 |
| 6.3 Reproductive development and function | 198 |
| 6.3.1 Human studies | 198 |
| 6.3.2 Animal studies | 202 |
| 6.3.2.1 Malformations of reproductive organs | 202 |
| 6.3.2.2 Anogenital distance | 203 |
| 6.3.2.3 Nipple/areola retention | 204 |
| 6.3.2.4 Sexual maturation and puberty | 204 |

| | | |
|---------|--|-----|
| 6.3.2.5 | Fertility | 204 |
| 6.3.2.6 | Histopathology of reproductive organs | 206 |
| 6.3.2.7 | Sperm quality and estrous cyclicity | 207 |
| 6.4 | Neurological and behavioural effects | 207 |
| 6.4.1 | Human studies | 207 |
| 6.4.2 | Animal studies | 208 |
| 6.4.2.1 | Motor activity | 208 |
| 6.4.2.2 | Motor and sensory functions | 209 |
| 6.4.2.3 | Learning and memory | 209 |
| 6.4.2.4 | Evaluation of effects | 210 |
| 6.5 | Cancer | 211 |
| 6.5.1 | Human studies | 211 |
| 6.5.2 | Animal studies | 212 |
| 6.6 | Immune system effects | 212 |
| 6.6.1 | Human studies | 212 |
| 6.6.2 | Animal studies | 213 |
| 6.7 | Respiratory system effects | 213 |
| 6.7.1 | Human studies | 213 |
| 6.7.2 | Animal studies | 213 |
| 6.8 | Haematopoietic/cardiovascular, hepatic/renal, skin/musculoskeletal, and metabolic/endocrine system effects | 214 |
| 6.8.1 | Human studies | 214 |
| 6.8.2 | Animal studies | 214 |
| 6.9 | Summary and conclusions | 214 |
| 7. | IMPLICATIONS AND STRATEGIES FOR RISK ASSESSMENT FOR CHILDREN | 217 |
| 7.1 | Introduction | 217 |
| 7.2 | Problem formulation | 220 |
| 7.3 | Hazard identification | 221 |
| 7.3.1 | End-points and critical periods of exposure | 223 |
| 7.3.2 | Human studies | 224 |
| 7.3.3 | Relevance of animal studies for assessing potential hazards to children | 225 |
| 7.3.4 | Reversibility and latency | 229 |
| 7.3.5 | Characterization of the health-related database | 230 |
| 7.4 | Dose-response assessment | 230 |
| 7.4.1 | Application of health outcome data | 232 |

| | |
|--|-----|
| 7.4.2 Quantitative evaluation | 233 |
| 7.4.2.1 Tolerable daily intake (TDI) and reference dose (RfD)/reference concentration (RfC) approaches | 233 |
| 7.4.2.2 Benchmark dose (BMD)/benchmark concentration (BMC) approach | 236 |
| 7.4.2.3 Biologically based dose-response models | 236 |
| 7.4.2.4 Duration adjustment | 237 |
| 7.4.2.5 Toxicokinetics | 237 |
| 7.5 Exposure assessment | 238 |
| 7.5.1 Age-specific exposures | 238 |
| 7.5.2 Assessment methods | 240 |
| 7.6 Risk characterization | 242 |
| 7.7 Summary and conclusions | 244 |
| REFERENCES | 247 |
| ANNEX 1: WORKING DEFINITIONS OF KEY TERMS | 310 |
| RESUME, CONCLUSIONS ET RECOMMANDATIONS | 315 |
| RESUMEN, CONCLUSIONES Y RECOMENDACIONES | 323 |